S-1: Spyre Therapeutics Files for Resale of 33.4 Million Shares Following PIPE Investments

Spyre Therapeutics aims to register the resale of up to 33.4 million shares of its common stock by selling stockholders after recent private placements.

Summary

• Spyre Therapeutics has filed a registration statement for the resale of up to 33.4 million shares of its common stock by selling stockholders.
• The shares include common stock, shares issued upon conversion of Series A Preferred Stock, and shares issuable upon conversion of Series B Preferred Stock.
• These shares were issued in connection with the Asset Acquisition of Pre-Merger Spyre and subsequent PIPE investments in June and December 2023, and March 2024.
• Spyre will not receive any proceeds from the sale of these shares.
• The selling stockholders will determine the timing and method of disposing of the shares.
• The company's common stock is traded on The Nasdaq Global Select Market under the symbol SYRE.
• As of December 31, 2023, Spyre had 36,057,109 shares of common stock, 437,037 shares of Series A Preferred Stock, and 150,000 shares of Series B Preferred Stock outstanding.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, outlining the registration for resale of shares. The sentiment is neutral, with a slight positive leaning due to the completion of financing rounds, but tempered by the inherent risks associated with investing in a biopharmaceutical company.

Risks

• An investment in our securities involves a high degree of risk.
• The market price of our Common Stock has historically been volatile and may drop in the future.
• We may fail to obtain stockholder approval of the conversion of our Series B Preferred Stock.
• Future sales of shares by existing stockholders could cause our stock price to decline.

Future Outlook

The selling stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part.

Industry Context

The document indicates a strategic shift for Spyre Therapeutics towards developing next-generation therapeutics for inflammatory bowel disease (IBD), a market with increasing prevalence and evolving treatment paradigms.

Related Party Transactions

• The document mentions related party transactions with Paragon Therapeutics and Fairmount Funds Management LLC, including ongoing obligations under the Paragon Agreement and equity grants to Parapyre.

Stakeholder Impact

• The resale of shares may impact the share price and investment value for existing shareholders.
• The potential for new investors to enter the company through the selling stockholders.

Next Steps

• The selling stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices.

Key Dates

Keywords

resale, common stock, Series B Preferred Stock, registration statement, PIPE, Spyre Therapeutics, selling stockholders, conversion